How Metformin Influences Breast Cancer Risk
May 29, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Macrina Ghali, PharmD Candidate 2021, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences
Study examines the complex relationship between type 2 diabetes, metformin use, and breast cancer subtype.
Previous studies in women with type 2 diabetes found a 20% higher risk of breast cancer, which may be due to the activation of insulin and insulin-like growth factors on the breast tissue or through alterations in sex hormones. The mechanism of action of metformin may provide a benefit in breast cancer reduction by improving insulin sensitivity. In addition, metformin may inhibit cancer cell proliferation and invasion and enhance resistance to chemotherapy. However, little evidence is currently available regarding the association between metformin use and breast cancer risk. As the first-line treatment option according to both the American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE), the prevalent use of metformin may reveal a relationship between its use and the variable risk of developing different forms of breast cancer....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.